Shuttle Pharmaceuticals is at the forefront of developing innovative therapies aimed at enhancing cancer treatment outcomes, particularly in the fields of Radiation Oncology and Immuno-Oncology. The company focuses on creating first-in-class therapies that not only sensitize cancer cells to radiation but also protect normal tissues from radiation damage. Their platform technology is centered around the discovery and development of novel small molecules that modify the effects of ionizing radiation. This includes a robust pipeline of products, with two lead candidates in clinical stages and several others in preclinical development, supported by strategic collaborations in drug discovery and preclinical studies.

One of the key technologies being advanced by Shuttle Pharmaceuticals is Ropidoxuridine (IPdR), an orally available halogenated pyrimidine that enhances the sensitivity of cancer cells to radiation therapy. The mechanism involves the incorporation of its metabolite, IUdR, into the DNA of rapidly dividing cancer cells, leading to the formation of reactive uracil free radicals that cause lethal DNA damage upon radiation exposure. Additionally, the company is exploring selective HDAC inhibitors, such as SP-1-161 and SP-2-225, which target specific histone deacetylases to modulate gene expression related to DNA repair and immune response. These advancements aim to improve the efficacy of radiation therapy and activate anti-tumor immune responses, positioning Shuttle Pharmaceuticals as a leader in the development of next-generation cancer treatments.

United States

Shuttle Pharmaceuticals is a clinical-stage pharmaceutical company developing novel therapies and diagnostics to improve the outcomes for cancer patients treated with radiation therapy. Our technology sensitizes growing cancer cells, rendering them susceptible to the effects of radiation therapy, activates DNA damage and innate immune responses and offers the potential to integrate with checkpoint inhibitors and immune therapies. Our mass spectrometry-based diagnostics platform is focused on predicting clinical outcomes to inform clinical decisions for patients electing to receive radiation therapy for prostate cancer. 

Shuttle Pharmaceuticals

Company Details